Asymptomatic colorectal cancer with un-resectable liver metastases: Immediate colorectal resection or up-front systemic chemotherapy?

被引:122
作者
Muratore, Andrea
Zorzi, Daria
Bouzari, Hedayat
Amisano, Marco
Massucco, Paolo
Sperti, Elisa
Capussotti, Lorenzo
机构
[1] Ist Ric & Cura Canc, Div Surg Oncol, Candiolo, TO, Italy
[2] Ist Ric & Cura Canc, Div Med Oncol, Candiolo, TO, Italy
关键词
colorectal cancer; liver metastases; surgical management; chemotherapy;
D O I
10.1245/s10434-006-9146-1
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: About 20% of patients with colorectal cancer have synchronous un-resectable liver metastases. Resection of colorectal cancer in patients with moderate-severe symptoms is mandatory before starting chemotherapy. Surgical treatment of asymptomatic colorectal cancers is still a matter of discussion. Methods: From January 2000 to December 2004, we prospectively collected data on 35 consecutive patients who were treated straightaway by chemotherapy without primary tumor resection. All patients underwent FOLFOX6 as first-line chemotherapy. The aim of the study was to evaluate the rate of surgical complications related to un-resected colorectal tumor. Results: The mean interval between diagnosis and start of chemotherapy was 23.1 days (95% CI: 17.3-28.8). Fifteen of the 35 patients (42.9%) were down-staged to surgery; the mean interval between chemotherapy start and colon-rectum cancer resection was 6.5 months (95% CI: 5.5-7.5). None of them developed complications related to the primary tumor during chemotherapy. Of the other 20 patients who did not undergo any curative surgery, 16 received a second line chemotherapy and 10 a third line: six patients are alive and without intestinal symptoms (mean follow up 22.5 months, 95% CI: 11.2-33.9). Only one patient (2.8%) developed clinical signs of intestinal occlusion 5.6 months from the start of chemotherapy and required urgent colostomy. Conclusions: The rate of complications related to the non-resected colorectal tumor is very low using oxaliplatin as first line chemotherapy. Non-operative management of asymptomatic colorectal cancers with un-resectable liver metastases is a safe approach.
引用
收藏
页码:766 / 770
页数:5
相关论文
共 25 条
[1]   Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: A North Central Cancer Treatment Group Phase II study [J].
Alberts, SR ;
Horvath, WL ;
Stcrnfeld, WC ;
Goldberg, RM ;
Mahoney, MR ;
Dakhil, SR ;
Levitt, R ;
Rowland, K ;
Nair, S ;
Sargent, DJ ;
Donohue, JH .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (36) :9243-9249
[2]   NATURAL-HISTORY OF PATIENTS WITH UNTREATED LIVER METASTASES FROM COLORECTAL-CANCER [J].
BENGTSSON, G ;
CARLSSON, G ;
HAFSTROM, L ;
JONSSON, P .
AMERICAN JOURNAL OF SURGERY, 1981, 141 (05) :586-589
[3]   Treatment strategy for patients with colorectal cancer and synchronous irresectable liver metastases [J].
Benoist, S ;
Pautrat, K ;
Mitry, E ;
Rougier, P ;
Penna, C ;
Nordlinger, B .
BRITISH JOURNAL OF SURGERY, 2005, 92 (09) :1155-1160
[4]   What is the best treatment for stage IV colorectal cancer? [J].
Cohen, AM .
ANNALS OF SURGICAL ONCOLOGY, 2005, 12 (08) :581-582
[5]  
Colorectal Canc Collaborative Grp, 2000, BMJ-BRIT MED J, V321, P531
[6]   Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer [J].
de Gramont, A ;
Figer, A ;
Seymour, M ;
Homerin, M ;
Hmissi, A ;
Cassidy, J ;
Boni, C ;
Cortes-Funes, H ;
Cervantes, A ;
Freyer, G ;
Papamichael, D ;
Le Bail, N ;
Louvet, C ;
Hendler, D ;
de Braud, F ;
Wilson, C ;
Morvan, F ;
Bonetti, A .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (16) :2938-2947
[7]   FACTORS AFFECTING SURVIVAL IN PATIENTS PRESENTING WITH SYNCHRONOUS HEPATIC METASTASES FROM COLORECTAL-CANCER - A CLINICAL AND COMPUTER-ANALYSIS [J].
FINAN, PJ ;
MARSHALL, RJ ;
COOPER, EH ;
GILES, GR .
BRITISH JOURNAL OF SURGERY, 1985, 72 (05) :373-377
[8]   Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery [J].
Giacchetti, S ;
Itzhaki, M ;
Gruia, G ;
Adam, R ;
Zidani, R ;
Kunstlinger, F ;
Brienza, S ;
Alafaci, E ;
Bertheault-Cvitkovic, F ;
Jasmin, C ;
Reynes, M ;
Bismuth, H ;
Misset, JL ;
Lévi, F .
ANNALS OF ONCOLOGY, 1999, 10 (06) :663-669
[9]   FACTORS INFLUENCING SURVIVAL IN PATIENTS WITH HEPATIC METASTASES FROM ADENOCARCINOMA OF THE COLON OR RECTUM [J].
GOSLIN, R ;
STEELE, G ;
ZAMCHECK, N ;
MAYER, R ;
MACINTYRE, J .
DISEASES OF THE COLON & RECTUM, 1982, 25 (08) :749-754
[10]   Neoadjuvant interleukin-12 immunogene therapy protects against cancer recurrence after liver resection in an animal model [J].
Jarnagin, WR ;
Delman, K ;
Kooby, D ;
Mastorides, S ;
Zager, J ;
Brennan, MF ;
Blumgart, LH ;
Federoff, H ;
Fong, Y .
ANNALS OF SURGERY, 2000, 231 (05) :762-769